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Dobutamine stress echocardiography is a well-established 
method to assess coronary artery disease, of which sensitivity 
has been enhanced by adding atropine at the end of the 
protocol. Individuals with glaucoma, a disease with a high 
prevalence in patients with cardiac diseases older than 40 years, 
cannot benefit from the use of atropine as it is contraindicated 
for this group of patients. Additionally, these individuals are 
often treated with topical betablockers (eye drops), which can 
have systemic effects by decreasing cardiac frequency, blood 
pressure and pulmonary capacity. The aim of our study was to 
verify whether a possible systemic effect caused by the use of 
these eye drops, yielding a low chronotropic response, could 
result in inconclusive dobutamine stress echocardiography in 
patients with glaucoma.
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stress test (EST)8,9. To date, there have been no references 
regarding the influence of this drug on dobutamine-stress 
echocardiography.
The aim of our study was to verify whether the occurrence 
of a possible systemic effect of topic betablockers, resulting 
in low chronotropic response, could yield inconclusive 
results at the dobutamine-stress echocardiography in 
patients with glaucoma.
Methods
Forty-two patients who were submitted to pharmacological-
stress echocardiography for diagnosis or evaluation of known 
coronary artery disease were studied. Of the 42 patients, 
21 had glaucoma. The control group (CG) consisted of the 
other 21 patients. Among the 21 patients with glaucoma, 
14 used topic betablocker (BB group) and 7 used eye drops 
based on other drugs (NB group). The patients were age-
paired and none of them were using oral betablocker at the 
time of the examination. Those who had previously used 
this type of medication were advised to interrupt it 7 days 
before the test.
All of the patients were submitted to at-rest HR and 
BP assessment every three minutes during and after the 
infusion. According to the standardized norms, a complete 
echocardiography was carried out and a digital system 
captured images at rest and at the infusion peak 5. Dobutamine 
was administered as a continuous infusion, in progressive 
doses of 10, 20, 30 up to 40 ug/kg/min. Atropine, however, 
was not administered to any of the patients. The aims of 
the examination were to attain submaximal HR (85% of the 
maximum HR) or the end of the protocol with the maximum 
dose of infusion, or the presence of ischemia observed by the 
alteration of the regional myocardial contractility. 
The test was interrupted earlier in case of severe ventricular 
arrhythmia, presence of supra-unleveling of the ST segment > 
2 mm at the electrocardiogram, increase of systolic pressure > 
210 mmHg or diastolic pressure > 110 mmHg, or accentuated 
hypotension. The test was considered inconclusive when 
the target HR was not reached or when was premature 
interruption due to the presence of limiting side effects such 
as arrhythmia, hypertension and its consequences, such as 
headache, nausea and vomiting.
Statistical analysis - The qualitative variables were 
determined as absolute and relative frequency, whereas the 
quantitative variables were determined as means and standard 
deviation (SD). The comparisons between the groups were 
Introduction
The dobutamine-atropine stress echocardiography is a 
broadly disseminated and well–established diagnostic method 
for coronary artery disease1. It is known that the use of systemic 
betablockers can interfere with the test result by decreasing the 
chronotropic response and reducing the diagnostic accuracy 
of the method2. The addition of atropine at the end of the 
dobutamine infusion protocol increases heart rate (HR) and 
consequently, the test sensitivity, especially in patients who use 
oral betablockers3,4, and has been systematically used, except 
in patients with prostatism and closed-angle glaucoma, which 
are contraindications to its use5.
Glaucoma is a disease with a high prevalence after 40 years 
of age; it is commonly observed in patients with cardiovascular 
disease and its treatment consists in the topic use of eye drops 
with several drugs, and among them betablockers, as their 
base6. Prior studies have reported that topic betablockers can 
have systemic effects, decreasing HR, blood pressure (BP) and 
pulmonary capacity, and that they are potentially capable of 
attenuating the stress-induced HR increase at the ergometric 
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performed by the chi-square test or Fisher’s test. The ANOVA 
(analysis of variance) was used for homogenous variance. 
Tukey’s test was used for multiple comparisons. Comparisons 
between the groups at different moments were carried out by 
univariate analysis. A value of p < 0.05 was considered to be 
statistically significant. 
Results
There was no statistical difference between the groups 
regarding the demographical characteristics such as gender, 
presence of hypertension, diabetes, smoking, dyslipidemia 
and previous history of acute myocardial infarction (Table 1). 
All patients were paired by age. 
The analysis of the systolic arterial pressure (SAP) showed 
that the groups presented similar SAP at rest and that the 
pressure increase at the infusion peak occurred equivalently, 
with no statistical difference among them (p=ns).
Table 1 - Demographical characteristics
Groups BB (n=14)
NB 
(n=7)
CG 
(n=21) p  value
Age 65 ± 9 71 ± 7 63 ± 8 NS
Male 36% 14% 24% NS
Hypertension 78% 71% 57% NS
Diabetes 
mellitus 36% 14% 29% NS
Dyslipidemia 64% 86% 52% NS
Smoking 0 0 19% NS
Previous AMI 21% 14% 14% NS
EF>55% 64% 86% 81% NS
AMI - acute myocardial infarction; EF - ejection fraction; NS - non-
significant.
Table 2 - Hemodynamic variables at rest and dobutamine-stress echocardiography results in the different groups
Groups BB (n=14) NB (n=7) CG (n=21) p values
HR at rest 69 ± 2 70 ± 3 71 ± 2 NS
Peak HR 72 ± 2 130 ± 10 133 ± 12 < 0.001
Diastolic BP r 90.7 ± 9 87.1 ± 7.6 86.2 ± 6.7 NS
Diastolic BP p 95 ± 11.6 87.1 ± 13.8 88.6 ± 7.3 NS
Systolic BP r 152 ± 20.4 159 ± 22 142 ± 16 NS
Systolic BP p 171 ± 36 161 ± 17 155 ± 22 NS
Dob 40ug/Kg/min 29% 29% 33% NS
Inconclusive tests 11 (79%) 0 0 < 0.001
Conclusive tests 3 (21.4%) 7 (100%) 21 (100%) < 0.001
Positive tests 1 (33%) 3 (40%) 7 (33%) NS
Side effects 10 (71%) 1 (14%) 3 (14%) < 0.001
HR - heart rate; BP - blood pressure; r - at rest; p - at peak of dobutamine infusion; Dob - dose of infused dobutamine; p< 0.05 significant; NS - non-significant. 
Values expressed in percentages refer to the number of patients in each group that used the maximum dose of dobutamine.
Although the BB group presented a higher diastolic arterial 
pressure (DAP) at rest, as well as at the peak when compared 
to the other groups, this difference was not statistically 
significant (p=ns).
On the other hand, the heart rate (HR) at rest was similar 
in all groups (p=ns), but it was significantly lower in the BB 
group at the infusion peak when compared to the other 
groups (p<0.05). This result confirms the systemic effect of 
the betablocker on the dobutamine-induced HR increment. 
The data on pressure and HR are summarized in Table 2.
All of the tests from the NB and CG groups were conclusive. 
However, only 3 tests were conclusive among the 14 patients 
from the BB group. Eleven patients presented inconclusive tests 
due to the lack of isolated chronotropic response (n=1) and/or 
associated to limiting side effects such as hypertension and 
headache (n=8) or ventricular arrhythmia (n=2) (Table 2).
The ejection fraction (EF) was equivalent in the three 
groups, with no statistical difference among them (p=ns) (Table 
1). Among the 31 conclusive tests, 11 were positive and 20 
were negative for ischemia. Of the 11 positive tests, 7 were 
from the CG, 3 from the NG group and 1 was from the BB 
group (p=ns) (Table 2).
Discussion
Our results show that the use of topic betablockers in 
patients with glaucoma can interfere with the results of 
the dobutamine-stress echocardiography test, resulting in 
an ineffective chronotropic response and, consequently, in 
inconclusive tests. This effect had been previously observed 
by authors who used the ergometric test as the stressor 
agent8,9. However, there are no studies indicating the 
same effect in patients submitted to pharmacological-stress 
echocardiography.
It is known that the use of systemic betablockers can 
interfere with the results of the pharmacological-stress 
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echocardiography by preventing HR increase, causing arterial 
hypertension and headache during the test2. The addition of 
atropine to the dobutamine infusion protocol decreased the 
number of inconclusive tests and is now currently performed 
as early as possible10. However, since the proposal of its 
inclusion in the original protocol and the establishment of its 
contraindications, there have been no reports in the literature 
on the results of pharmacological-stress echocardiography in 
patients with glaucoma, who could not benefit from the use 
of atropine. This is probably due to the fact that many patients 
with cardiac disease and glaucoma are submitted to this test 
under the use of oral betablocker, and the lack of chronotropic 
response is attributed to the oral medication, instead of the 
topic presentation. The present study was only possible 
because the use of betablockers was systematically withdrawn, 
excluding any possibility of sample “contamination”.
Clinical significance - Although the coexistence of 
respiratory or cardiovascular disease is a contraindication to 
the use of topical betablockers, cardiologists do not commonly 
take these effects into account in clinical practice and do not 
pay special attention to the possible drug interactions between 
these eye drops and other pharmaceuticals. The use of this 
kind of eye drops is very disseminated in our country due to its 
low cost. Therefore, the choice of treatment for these patients’ 
cardiopathy should be considered with caution, considering 
the type of eye drops used by these patients.  
Additionally, other diagnostic tests for coronary artery 
disease can possibly present inconclusive results, increasing 
the cost of treatment. Another question to be considered is 
the contraindication of atropine for patients with closed-angle 
glaucoma, exclusively. In our country, patients frequently 
do not know what type of glaucoma they have and the 
communication with the ophthalmologist does not take place. 
To our knowledge, atropine is systematically contraindicated 
for patients with any type of glaucoma in echocardiography 
laboratories. We do not know whether further knowledge 
about this affection would prevent the contraindication of 
atropine, which is so useful for the effective test performance. 
Additionally, it is necessary to study the possibility of 
withdrawing the topic betablocker before carrying out the 
stress echocardiography and possibly any diagnostic test during 
which it is necessary to increase heart rate.
Study limitations - The present study sample size is small 
and thus, it is not possible to establish whether the deleterious 
effect of the topic betablocker is dose-dependent and/or time-
dependent. Furthermore, due to the study design, we do not 
know whether this drug withdrawal would be indicated during 
the performance of dobutamine stress echocardiography. The 
coexistence of glaucoma and coronary artery disease at older 
age ranges is a relevant fact that justifies further research. 
Therefore, it is necessary to increase the sample size and to 
consider the substitution of the topic betablocker for other 
types of medication.
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